US Drug Patent 6,046,202: Claim Scope, Expiration, and Patent Landscape for Troglitazone, Pioglitazone, and Rosiglitazone

US Patent 6,046,202 covers methods of treating a narrowly defined form of insulin resistance with three thiazolidinediones: troglitazone, pioglitazone, and rosiglitazone. The claims are use claims, not composition, formulation, manufacturing, or dosing claims. Each claim requires both a specified patient phenotype and administration of the named active ingredient in a therapeutically effective amount.

The patent does not create a current blocking right for generic pioglitazone or rosiglitazone products because the patent term has expired. Troglitazone was withdrawn from the U.S. market for safety reasons in 2000. The principal commercial relevance of US 6,046,202 is historical: it illustrates an early method-of-use patent directed to insulin sensitization rather than merely glycemic control.

What does US Patent 6,046,202 claim?

The patent contains three independent method claims:

Claim	Active ingredient	Claimed disease state	Claim type
1	(+)-Troglitazone	Insulin resistance with hyperinsulinemia and failure to respond to exogenous insulin	Method of treatment
2	Pioglitazone	Same patient phenotype	Method of treatment
3	Rosiglitazone	Same patient phenotype	Method of treatment

The claims require the following elements:

A patient has insulin resistance.
The insulin resistance is characterized by hyperinsulinemia.
The patient fails to respond to exogenous insulin.
The named thiazolidinedione is administered.
The amount administered is therapeutically effective.

A product does not infringe merely because it contains a thiazolidinedione. The claimed patient condition and treatment method must also be present.

How should Claim 1 for troglitazone be interpreted?

Claim 1 is directed to the (+)-enantiomeric troglitazone structure identified in the claim. It is not drafted as a broad claim to every troglitazone formulation or every use of troglitazone.

The structural limitation is significant. The claim identifies:

The chroman-based vitamin E-like moiety;
The hydroxy-substituted, tetramethyl benzopyran structure;
The phenylmethyl linker;
The 2,4-thiazolidinedione pharmacophore; and
The positive stereochemical form designated "(+)."

A method using a different active compound would not fall within Claim 1, even if the compound had the same pharmacologic mechanism. A racemate or opposite stereoisomer would raise a separate claim-construction issue because the claim expressly identifies the (+) form.

Troglitazone was marketed in the United States as Rezulin. The FDA requested withdrawal of Rezulin in March 2000 after liver toxicity concerns, and the product was removed from the U.S. market shortly before or around the patent’s issuance period [1, 2].

What commercial products were affected by the troglitazone claim?

Product	Active ingredient	U.S. status
Rezulin	Troglitazone	Withdrawn from U.S. market in 2000
Actos	Pioglitazone	Approved and later available in generic form
Avandia	Rosiglitazone	Approved, with later regulatory restrictions and generic availability

The withdrawal of troglitazone substantially reduced the practical commercial value of Claim 1. The claim remains relevant as a historical patent right, but it no longer supports a current U.S. market exclusivity strategy.

How broad are Claims 2 and 3 for pioglitazone and rosiglitazone?

Claims 2 and 3 are composition-specific method claims. Each names a single active molecule by chemical structure:

Claim 2 covers pioglitazone treatment.
Claim 3 covers rosiglitazone treatment.

Neither claim covers the other active ingredient. Pioglitazone administration cannot infringe Claim 3, and rosiglitazone administration cannot infringe Claim 2.

The claims do not expressly limit:

Tablet, capsule, liquid, or injectable dosage form;
Route of administration;
Specific dose;
Treatment duration;
Monotherapy or combination therapy;
Adult or pediatric patients;
Type 1 or type 2 diabetes;
A particular degree of insulin resistance; or
A particular formulation excipient.

The absence of these limitations makes the claims potentially broad with respect to the manner of administration. The claims remain narrow, however, because the patient must have hyperinsulinemia and must fail to respond to exogenous insulin.

What patient population is covered by US 6,046,202?

The patient limitation is the central narrowing feature of all three claims.

The claims do not cover every patient with diabetes or every patient with insulin resistance. They require a patient whose condition is characterized by:

Hyperinsulinemia; and
Failure to respond to exogenous insulin.

This language describes a clinically severe insulin-resistant population. Ordinary type 2 diabetes patients treated with a thiazolidinedione would not necessarily satisfy the claim unless the evidence established both required characteristics.

Does the claim cover ordinary type 2 diabetes treatment?

Not automatically. A physician’s prescription of pioglitazone or rosiglitazone for type 2 diabetes would not, by itself, establish infringement. The patent claims a defined insulin-resistant phenotype, not the broad diagnosis of type 2 diabetes.

For an enforcement theory, the patent owner would need evidence concerning the patient’s hyperinsulinemia, response to exogenous insulin, and administration of the claimed drug. Product labeling alone would not necessarily establish that every treated patient falls within the claim.

What does “therapeutically effective amount” add to the claims?

“Therapeutically effective amount” is a functional treatment limitation. It requires an amount sufficient to produce the claimed therapeutic effect, rather than any administration of a trace quantity.

The claims do not specify milligram strength or dosing frequency. The limitation therefore avoids a fixed-dose restriction but introduces an efficacy-related requirement. A dose that is too low to treat the insulin resistance would not satisfy the limitation.

For generic-drug litigation, this distinction matters. A generic product label may recommend a dosage that is capable of practicing the method, but the patent analysis still depends on whether the labeled use corresponds to the full patient population and therapeutic conditions recited in the claim.

Is US 6,046,202 a formulation patent or a method-of-use patent?

US 6,046,202 is a method-of-use patent.

It does not claim:

A tablet containing pioglitazone;
A controlled-release formulation;
A salt, polymorph, or crystal form;
A combination with metformin or insulin;
A manufacturing process;
A pharmaceutical composition; or
A drug-delivery system.

This distinction limits its ability to delay generic approval. A formulation patent can block a particular dosage form even after the active ingredient patent expires. US 6,046,202 does not provide that type of protection.

When did US Patent 6,046,202 lose exclusivity?

US 6,046,202 issued on April 4, 2000. It is no longer enforceable as a live U.S. patent. The patent was filed under the U.S. patent-term framework applicable to its filing period, and the maximum ordinary term would have ended no later than 2020 based on the patent’s pre-issuance filing date. Any possible patent-term adjustment or extension would not restore current enforceability decades later.

Event	Date or status
Patent issued	April 4, 2000
Active patent term	Historical only
Current enforceability	Expired
Current generic blocking effect	None
Potential current PTE/PTE-based barrier	None identified from the claimed patent

Patent expiration removes infringement liability for post-expiration conduct. It does not erase historical infringement claims that accrued while the patent was enforceable, subject to applicable statutes of limitation and other defenses.

What is the Orange Book status of US 6,046,202?

US 6,046,202 is not a current source of Orange Book exclusivity for pioglitazone or rosiglitazone.

The FDA Orange Book lists patents and exclusivities associated with approved drug products, but listing status does not extend the life of an expired patent. Even if a patent was historically listed against an approved product, an expired listing cannot prevent approval or marketing of a generic product after patent expiration [3].

The relevant branded products were:

Brand	Active ingredient	Regulatory relevance
Rezulin	Troglitazone	Withdrawn; no current U.S. product market
Actos	Pioglitazone	Generic competition established
Avandia	Rosiglitazone	Generic competition established; regulatory restrictions affected use

A current ANDA applicant for pioglitazone or rosiglitazone would focus on unexpired Orange Book-listed patents, regulatory exclusivities, and product-specific requirements. US 6,046,202 would not ordinarily create a current Paragraph IV barrier.

Were Paragraph IV challenges relevant to this patent?

Paragraph IV litigation could have been relevant before expiration if the patent had been listed against an approved product and a generic applicant certified that the patent was invalid, unenforceable, or not infringed.

The statutory framework under the Hatch-Waxman Act permits a generic applicant to submit a Paragraph IV certification against an unexpired listed patent. A notice letter can trigger patent litigation and a statutory 30-month stay under specified conditions [4].

For US 6,046,202, the practical position is different today:

The patent has expired.
A new Paragraph IV challenge cannot create a current market-exclusion period for this patent.
Any historical litigation would have concerned pre-expiration generic entry.
A current generic applicant would not need to overcome this patent as an enforceable barrier.

The claim language could have supported a non-infringement position based on the patient limitation. A generic label that did not direct treatment of patients with hyperinsulinemia who failed to respond to exogenous insulin could have reduced induced-infringement risk.

What patent litigation and settlement issues affect the patent?

The supplied claims do not establish a litigation history, settlement agreement, license, assignment record, or terminal disclaimer. Those matters cannot be inferred from claim language.

The patent’s litigation risk during its active term would have centered on four issues:

Whether pioglitazone or rosiglitazone labeling instructed treatment of the claimed patient population;
Whether the claimed patient characteristics were objectively established;
Whether “failure to respond to exogenous insulin” was satisfied by clinical records or labeling;
Whether the patent was valid in view of prior disclosures concerning thiazolidinediones and insulin sensitization.

The claims are vulnerable to design-around arguments because the active ingredients are expressly named and the patient population is unusually specific. A defendant could contest the patient limitation, the therapeutic-effect limitation, or both.

How strong was the patent estate?

The patent estate appears narrow in breadth but potentially meaningful at the time of issuance because it covered three commercially important insulin-sensitizing drugs in a single patent.

Strength factor	Assessment
Number of independent claims	Three
Active ingredients covered	Three named thiazolidinediones
Formulation coverage	None apparent
Manufacturing coverage	None apparent
Dosage coverage	No fixed dose
Patient-population limitation	Strong narrowing limitation
Current enforceability	None
Generic blocking value today	None
Historical commercial scope	Potentially material

The estate’s principal weakness is lack of ancillary claims. There are no apparent composition, formulation, salt, polymorph, combination, or manufacturing claims in the three claims provided. A patent portfolio with only method claims would have been easier to avoid through label design, alternative patient selection, or a non-infringing indication.

What generic entry risks existed for Actos and Avandia?

The patent created potential risk for generic pioglitazone and rosiglitazone products only while it remained unexpired and only if the generic product’s labeling or induced use covered the claimed patient population.

Potential generic-entry scenarios included:

Scenario	Patent risk during term
Generic pioglitazone labeled broadly for insulin resistance	Possible Claim 2 exposure
Generic rosiglitazone labeled broadly for insulin resistance	Possible Claim 3 exposure
Label limited to ordinary type 2 diabetes without claimed phenotype	Lower method-of-use risk
Product marketed after patent expiration	No infringement liability from this patent
Generic formulation with different excipients	No protection from this patent
Combination product using a different active ingredient	Outside the literal claims

The strongest historical enforcement theory would have involved a label or promotional program expressly directing treatment of severely insulin-resistant, hyperinsulinemic patients who failed exogenous insulin.

Does the patent create biosimilar risk?

No. Troglitazone, pioglitazone, and rosiglitazone are small-molecule drugs, not biologics. The relevant competitive pathway is the ANDA pathway for generic drugs, not the abbreviated biologics license application pathway for biosimilars.

Biosimilar concepts such as interchangeable designation, reference-product exclusivity, and patent dance procedures under the Biologics Price Competition and Innovation Act do not apply to this patent’s active ingredients.

What licensing and revenue exposure did the patent create?

The claims could have supported licensing value during the commercial life of the drugs, particularly if the patent owner held rights to the discovery that thiazolidinediones could treat severe insulin resistance.

Potential licensees would have included:

Manufacturers of troglitazone;
Pioglitazone developers;
Rosiglitazone developers;
Combination-product sponsors; and
Generic applicants seeking pre-expiration entry.

The commercial value declined sharply after:

Troglitazone withdrawal;
Generic entry into the thiazolidinedione market;
Expiration of the patent; and
Safety restrictions affecting rosiglitazone.

No current revenue exposure remains attributable to US 6,046,202 itself. Any present valuation would relate to historical damages, archival licensing rights, or portfolio analysis rather than ongoing exclusivity.

What geographic coverage does US 6,046,202 provide?

The patent provides U.S. coverage only. It does not establish rights in Europe, Japan, Canada, or other jurisdictions.

Foreign equivalents would require separate applications, grants, maintenance payments, and national-phase analysis. The U.S. claims cannot be used to block manufacturing, sale, or use outside the United States.

Key Takeaways

US 6,046,202 claims treatment methods using troglitazone, pioglitazone, or rosiglitazone.
Each claim requires insulin resistance characterized by hyperinsulinemia and failure to respond to exogenous insulin.
The patent does not claim formulations, doses, combinations, manufacturing methods, or delivery systems.
Claims 2 and 3 are the most commercially relevant because they cover pioglitazone and rosiglitazone.
Troglitazone was withdrawn from the U.S. market in 2000 because of liver-safety concerns.
The patent is expired and does not create a current U.S. generic-entry barrier.
No biosimilar pathway is implicated because all three products are small molecules.
Historical infringement risk would have focused on labeling, induced use, patient characterization, and the meaning of “therapeutically effective amount.”
Current commercial value is negligible as an exclusivity right.

FAQs About US Patent 6,046,202

Can a generic pioglitazone product infringe US 6,046,202 today?

No current infringement liability arises from an expired patent. Historical conduct occurring before expiration could be analyzed separately.

Does US 6,046,202 cover metformin combinations with pioglitazone?

The claims provided do not require or claim metformin. A combination product would be evaluated based on whether it administers pioglitazone to the claimed patient population, but the patent is no longer enforceable.

Does the patent cover all patients with insulin resistance?

No. The claims require hyperinsulinemia and failure to respond to exogenous insulin in addition to insulin resistance.

Was troglitazone’s withdrawal caused by patent problems?

No. Troglitazone was withdrawn because of serious hepatotoxicity concerns, not because of patent invalidity or expiration.

Can the patent be used to block a rosiglitazone formulation patent?

No. US 6,046,202 does not create current blocking rights, and its claims are directed to treatment methods rather than formulation technology.

References

U.S. Patent No. 6,046,202. (2000). Treatment of insulin resistance with thiazolidinediones. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2000). FDA announces withdrawal of Rezulin. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	198045	⤷ Start Trial
Austria	303147	⤷ Start Trial
Austria	376829	⤷ Start Trial
Austria	489952	⤷ Start Trial
Australia	1770997	⤷ Start Trial
Australia	1771097	⤷ Start Trial
Australia	678291	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,046,202

Summary for Patent: 6,046,202